Citation
Tumbarello, Mario, et al. "Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused By Klebsiella Pneumoniae Carbapenemase-producing K. Pneumoniae." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 68, no. 3, 2019, pp. 355-364.
Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355-364.
Tumbarello, M., Trecarichi, E. M., Corona, A., De Rosa, F. G., Bassetti, M., Mussini, C., Menichetti, F., Viscoli, C., Campoli, C., Venditti, M., De Gasperi, A., Mularoni, A., Tascini, C., Parruti, G., Pallotto, C., Sica, S., Concia, E., Cultrera, R., De Pascale, G., ... Viale, P. (2019). Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 68(3), 355-364. https://doi.org/10.1093/cid/ciy492
Tumbarello M, et al. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused By Klebsiella Pneumoniae Carbapenemase-producing K. Pneumoniae. Clin Infect Dis. 2019 01 18;68(3):355-364. PubMed PMID: 29893802.
TY - JOUR
T1 - Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
AU - Tumbarello,Mario,
AU - Trecarichi,Enrico Maria,
AU - Corona,Alberto,
AU - De Rosa,Francesco Giuseppe,
AU - Bassetti,Matteo,
AU - Mussini,Cristina,
AU - Menichetti,Francesco,
AU - Viscoli,Claudio,
AU - Campoli,Caterina,
AU - Venditti,Mario,
AU - De Gasperi,Andrea,
AU - Mularoni,Alessandra,
AU - Tascini,Carlo,
AU - Parruti,Giustino,
AU - Pallotto,Carlo,
AU - Sica,Simona,
AU - Concia,Ercole,
AU - Cultrera,Rosario,
AU - De Pascale,Gennaro,
AU - Capone,Alessandro,
AU - Antinori,Spinello,
AU - Corcione,Silvia,
AU - Righi,Elda,
AU - Losito,Angela Raffaella,
AU - Digaetano,Margherita,
AU - Amadori,Francesco,
AU - Giacobbe,Daniele Roberto,
AU - Ceccarelli,Giancarlo,
AU - Mazza,Ernestina,
AU - Raffaelli,Francesca,
AU - Spanu,Teresa,
AU - Cauda,Roberto,
AU - Viale,Pierluigi,
PY - 2018/03/28/received
PY - 2018/06/06/accepted
PY - 2018/6/13/pubmed
PY - 2020/3/7/medline
PY - 2018/6/13/entrez
SP - 355
EP - 364
JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
JO - Clin Infect Dis
VL - 68
IS - 3
N2 - Background: Ceftazidime-avibactam (CAZ-AVI) has been approved in Europe for the treatment of complicated intra-abdominal and urinary tract infections, as well as hospital-acquired pneumonia, and for gram-negative infections with limited treatment options. CAZ-AVI displays in vitro activity against Klebsiella pneumoniae carbapenemase (KPC) enzyme producers, but clinical trial data on its efficacy in this setting are lacking. Methods: We retrospectively reviewed 138 cases of infections caused by KPC-producing K. pneumoniae (KPC-Kp) in adults who received CAZ-AVI in compassionate-use programs in Italy. Case features and outcomes were analyzed, and survival was then specifically explored in the large subcohort whose infections were bacteremic. Results: The 138 patients started CAZ-AVI salvage therapy after a first-line treatment (median, 7 days) with other antimicrobials. CAZ-AVI was administered with at least 1 other active antibiotic in 109 (78.9%) cases. Thirty days after infection onset, 47 (34.1%) of the 138 patients had died. Thirty-day mortality among the 104 patients with bacteremic KPC-Kp infections was significantly lower than that of a matched cohort whose KPC-Kp bacteremia had been treated with drugs other than CAZ-AVI (36.5% vs 55.8%, P = .005). Multivariate analysis of the 208 cases of KPC-Kp bacteremia identified septic shock, neutropenia, Charlson comorbidity index ≥3, and recent mechanical ventilation as independent predictors of mortality, whereas receipt of CAZ-AVI was the sole independent predictor of survival. Conclusions: CAZ-AVI appears to be a promising drug for treatment of severe KPC-Kp infections, especially those involving bacteremia.
SN - 1537-6591
UR - https://www.unboundmedicine.com/medline/citation/29893802/Efficacy_of_Ceftazidime_Avibactam_Salvage_Therapy_in_Patients_With_Infections_Caused_by_Klebsiella_pneumoniae_Carbapenemase_producing_K__pneumoniae_
L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciy492
DB - PRIME
DP - Unbound Medicine
ER -